Centre Hospitalier Intercommunal Compiegne Noyon

Running trials

• Recruiting

  IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as post transplantation maintenance therapy in patients with newly-diagnosed myeloma

  2024-517325-43-00· Phase 2· Source

• Recruiting

  Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone

  NCT06561854· Phase 3· Source

• Recruiting

  A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment (EmpowHER 303)

  NCT06435429· Phase 3· Source

• Active, not recruiting

  OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT06016738· Phase 3· Source

• Recruiting

  Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study

  NCT05692999· Phase 3· Source

• Recruiting

  Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

  NCT05181735· Phase 1/2· Source

• Active, not recruiting

  PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patients aged 70 and older

  NCT02355379· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma2 recruiting
• Lung cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Myelodysplastic syndromes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

  NCT06122961· Source